Swiss healthcare giant Roche Pharma has announced plans to invest a minimum of 1.5 billion Swiss franc in India over the next five years, highlighting its long-term commitment to India.

The announcement was made by Francois du Toit, Area Head for CEETRIS (Central Eastern Europe, Turkiye, Russia and Indian Subcontinent), at the India-European Free Trade Association (EFTA) Prosperity Summit. Roche currently employs over 5,000 people in India and aims to channel the investment into three critical areas, including research and development (R&D). The company also plans to collaborate with flagship healthcare initiatives such as Ayushman Bharat to expand access to its innovative medicines and healthcare solutions to a broader patient base.

This commitment aligns with India’s growing role as both a major pharmaceutical market and a hub for innovation. The announcement coincided with the implementation of India’s free trade agreement with the EFTA bloc.